EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

4′-Fluorouridine inhibits alphavirus replication and infection in vitro and in vivo

Peiqi Yin iD, Nicholas A May, Laura Sandra Lello, Atef Fayed, M Guston Parks, Adam M Drobish, Sainan Wang, Meghan Andrews, Zachary Sticher, Alexander A Kolykhalov, Michael G Natchus, George R Painter und 3 weitere

mBio · 12.06.2024 · 15 (6)

DOI: 10.1128/mbio.00420-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 12.06.2024. Verfasst von Peiqi Yin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Virus Replication, Antiviral Agents, Chikungunya virus, Alphavirus. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chikungunya virus (CHIKV) is an enveloped, positive-sense RNA virus that has re-emerged to cause millions of human infections worldwide. In humans, acute CHIKV infection causes fever and severe muscle and joint pain. Chronic and debilitating arthritis and joint pain can persist for months to years. To date, there are no approved antivirals against CHIKV. Recently, the ribonucleoside analog 4′-fluorouridine (4′-FlU) was reported as a highly potent orally available inhibitor of SARS-CoV-2, respiratory syncytial virus, and influenza virus replication. In this study, we assessed 4′-FlU’s potency and breadth of inhibition against a panel of alphaviruses including CHIKV, and found that it broadly suppressed alphavirus production in cell culture. 4′-FlU acted on the viral RNA replication step, and the first 4 hours post-infection were the critical time for its antiviral effect. In vitro replication assays identified nsP4 as the target of inhibition. In vivo , treatment with 4′-FlU reduced disease signs, inflammatory responses, and viral tissue burden in mouse models of CHIKV and Mayaro virus infection. Treatment initiated at 2 hours post-infection was most effective; however, treatment initiated as late as 24–48 hours post-infection produced measurable antiviral effects in the CHIKV mouse model. 4′-FlU showed effective oral delivery in our mouse model and resulted in the accumulation of both 4′-FlU and its bioactive triphosphate form in tissues relevant to arthritogenic alphavirus pathogenesis. Together, our data indicate that 4′-FlU inhibits CHIKV infection in vitro and in vivo and is a promising oral therapeutic candidate against CHIKV infection. IMPORTANCE Alphaviruses including chikungunya virus (CHIKV) are mosquito-borne positive-strand RNA viruses that can cause various diseases in humans. Although compounds that inhibit CHIKV and other alphaviruses have been identified in vitro , there are no licensed antivirals against CHIKV. Here, we investigated a ribonucleoside analog, 4′-fluorouridine (4′-FlU), and demonstrated that it inhibited infectious virus production by several alphaviruses in vitro and reduced virus burden in mouse models of CHIKV and Mayaro virus infection. Our studies also indicated that 4′-FlU treatment reduced CHIKV-induced footpad swelling and reduced the production of pro-inflammatory cytokines. Inhibition in the mouse model correlated with effective oral delivery of 4′-FlU and accumulation of both 4′-FlU and its bioactive form in relevant tissues. In summary, 4′-FlU exhibits potential as a novel anti-alphavirus agent targeting the replication of viral RNA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Virus ReplicationAntiviral AgentsChikungunya virusAlphavirusAnimalsMiceUridineHumansChikungunya FeverDisease Models, AnimalCell LineChlorocebus aethiopsFemaleVero Cells

Stichwörter der Autor:innen

RNA replicationalphavirusantiviralchikungunya virusmayaro virus

Substanzen

Antiviral AgentsUridine

Autor:innen und Institutionen

  • Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Institute of Bioengineering, University of Tartu, Tartu, Estonia.
  • Emory Institute for Drug Development (EIDD), Atlanta, Georgia, USA.
  • Drug Innovations Ventures at Emory (DRIVE), Atlanta, Georgia, USA.
  • Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA.

ORCID-Profile: Peiqi Yin, Andres Merits, Margaret Kielian, Thomas E Morrison

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

Zitieren

APA

Yin, P., May, N. A., Lello, L. S., Fayed, A., Parks, M. G., Drobish, A. M., Wang, S., Andrews, M., Sticher, Z., Kolykhalov, A. A., Natchus, M. G., Painter, G. R., Merits, A., Kielian, M., & Morrison, T. E. (2024). 4′-Fluorouridine inhibits alphavirus replication and infection in vitro and in vivo. mBio, 15(6). https://doi.org/10.1128/mbio.00420-24

Vancouver

Yin P, May NA, Lello LS, Fayed A, Parks MG, Drobish AM, et al. 4′-Fluorouridine inhibits alphavirus replication and infection in vitro and in vivo. mBio. 2024;15(6). doi:10.1128/mbio.00420-24

BibTeX
@article{Yin2024,
  author = {Yin, Peiqi and May, Nicholas A and Lello, Laura Sandra and Fayed, Atef and Parks, M Guston and Drobish, Adam M and Wang, Sainan and Andrews, Meghan and Sticher, Zachary and Kolykhalov, Alexander A and Natchus, Michael G and Painter, George R and Merits, Andres and Kielian, Margaret and Morrison, Thomas E},
  title = {4′-Fluorouridine inhibits alphavirus replication and infection in vitro and in vivo},
  journal = {mBio},
  year = {2024},
  volume = {15},
  number = {6},
  doi = {10.1128/mbio.00420-24}
}
Kostenlos starten →